Deutsche Beteiligungs (DBAG) takes majority stake in Hipp Technology Group

Deutsche Beteiligungs AG (DBAG) has entered into a definitive agreement to acquire a majority stake in Hipp Technology Group, marking a significant entry into the medical contract manufacturing space. The transaction involves the acquisition of the majority interest previously held by the Swiss investment firm Endura Capital, with the financing provided by DBAG Fund VIII. A critical component of the deal structure is the retention of a significant minority stake by the founder and CEO, Markus Hipp, ensuring leadership continuity and alignment of interests. The strategic rationale for the acquisition is the transformation of Hipp Technology into a central platform for a broader international consolidation strategy. DBAG intends to leverage the company’s technical reputation and prime location in the Tuttlingen MedTech cluster to acquire complementary technologies and expand its global market presence. This "buy-and-build" approach is designed to capitalize on the increasing demand for specialized outsourcing in robotic surgery and orthopedics. The partnership will focus on scaling the current production capacity across its five sites while pursuing inorganic growth opportunities in Europe and beyond, professionalizing the group to serve a larger international client base of medical device manufacturers.